Telix Pharmaceuticals 1 article

Telix Pharmaceuticals is a radiopharmaceutical biotechnology company whose scientific profile centers on molecularly targeted radiation therapy, with tumor-targeted radionuclide delivery shaping how radiation is localized to disease tissue. The company pairs radiopharmaceuticals with radioligand theranostics, with PSMA-targeted prostate cancer imaging showing how molecular recognition is converted into localized radiation exposure. GenoMethods maps radionuclides, targeting ligands and named radiopharmaceuticals separately; the platform profile of Telix Pharmaceuticals also includes PET radiopharmaceutical diagnostics.

Biotechnology News & Analysis

October 7, 2026, 7:55 AM · 5 mins read

Telix Pharmaceuticals snaps up ITM Isotope Technologies in $2.35B deal, sparking September biotech buying spree

Telix’s $2.35 billion buyout of ITM Isotope Technologies tops a month packed with major biotech deals, as industry giants chase radiopharmaceuticals, next-gen antibodies, and new obesity drugs.